Table 4.
Parameter | Hb conc | RBC's Count | PCV | Platelets count | WBC x 1000 mm3 | Deferential white blood cells |
||||
---|---|---|---|---|---|---|---|---|---|---|
mg/dl | X million/mm3 | mm | X 1000/mm3 | Neutrophil | Lymphocytes | Monocytes | Eosinophil | Basophiles | ||
Normal groups | ||||||||||
Normal control | 11.5 ± 1.10 | 11.12 ± 1.00 | 41.12 ± 1.25 | 300 ± 1.41 | 7 ± 0.98 | 25.63 ± 0.69 | 65 ± 1.02 | 3.41 ± 1.24 | 4 ± 0.78 | 1.96 ± 0.30 |
S. yapa control group | 13 ± 1.11 | 10.65 ± 1.16 | 46 ± 0.97 | 296.67 ± 0.79 | 6.8 ± 0.28 | 28 ± 1.17 | 65 ± 1.75 | 3 ± 0.21 | 2 ± 0.10 | 2 ± 0.14 |
Ehrlich ascites carcinoma bearing mice | ||||||||||
Tumor bearing mice | 6.53 ± 0.96** | 7.24 ± 1.11** | 31.32 ± 1.52** | 100 ± 1.61** | 11.41 ± 1.00** | 60 ± 0.84** | 29 ± 0.67** | 5.50 ± 0.13** | 3 ± 0.09**a | 2.5 ± 0.14** |
5-Flourouracil | 7.11 ± 1.06* | 7.53 ± 0.97a | 38.54 ± 2.16* | 185 ± 1.86* | 9.24 ± 1.08* | 36.33 ± 2.11* | 56.24 ± 1.46* | 4.16 ± 0.74* | 2.27 ± 0.85*a | 1.0 ± 0.04 |
% change | +8.88% | +4.01% | +23.05% | +85% | −19.02% | −39.45% | +93.93% | −24.36% | −24.33% | −60% |
S. yapa treated mice | 10.07 ± 1.01*a | 7.89 ± 0.90a | 34.42 ± 1.28* | 220.87 ± 1.39* | 6.65 ± 0.92* | 42.75 ± 0.65* | 49.40 ± 1.75* | 2.90 ± 0.25* | 2.95 ± 0.05* | 2.0 ± 0.03* |
% change | +54.21% | +8.98% | +9.89% | +120% | −41.71% | −28.75% | +70.34%) | −47.27% | −1.6% | −20% |
Data are presented as mean ± SD followed with increasing or decreasing percentage as compared to tumor bearing mice. ANOVA one-way was used for data analysis followed by post Hoc test for multiple comparisons (n = 5, p < 0.05). Bearing mice were compared to –ve control group (**) while treated groups were compared to bearing group (*). Hb; hemoglobin, RBC's; red blood cell, PCV; packed cell volume, WBC; white blood cell. Percentages of increasing or decreasing was calculated as compared to bearing mice.